Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 7, 2019

A Novel Myelin Protein Zero variant in Charcot-Marie-Tooth Disease Type 2I (P3.4-038)

Hani Kushlaf
First published April 16, 2019,
Hani Kushlaf
1Neurology & Rehabilitation Medicine, University of Cincinnati Cincinnati OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A Novel Myelin Protein Zero variant in Charcot-Marie-Tooth Disease Type 2I (P3.4-038)
Hani Kushlaf
Neurology Apr 2019, 92 (15 Supplement) P3.4-038;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To describe the clinical presentation and a novel myelin protein zero (MPZ) pathogenic variant causing Charcot-Marie-Tooth disease type 2I (CMT2I) in an index patient and his father.

Background: Myelin protein zero is the major myelin structural protein made by schwann cells. MPZ mutations are known to cause autosomal dominant CMT2B, congenital hypomyelinating neuropathy, Distal Intermediate CMT (DI-CMT), and CMT2I/J.

Design/Methods: A 45-year-old man with a past medical history of hyperlipidemia and hypertension, presented with a four-year history of progressive bilateral foot numbness. The numbness is up to ankles and is associated with intermittent sharp shooting pain in feet. The patient’s father (77 years of age), who has a well-controlled diabetes, had symptoms of neuropathy since his mid-sixties. Mother and a 3-year-old son have no symptoms of neuropathy but paternal grandmother had neuropathy. Examination of the index patient revealed high arched feet, stocking distribution sensory loss to pinprick, light touch, and vibration up to ankles. Muscle strength and reflexes were normal as was sensory examination in arms, gait, pupillary reflexes and cerebellar exam.

Results: Vitamin B12, HbA1c, TSH, and serum protein electrophoresis/immunofixation were normal. Electrodiagnostic testing revealed mild sensory neuropathy and right chronic and mild S1 radiculopathy. MRI of the lumbar spine showed no significant central canal or foraminal narrowing. Genetic sequencing of 72 genes known to cause CMT identified a heterozygous (p.Tyr181Cys) variant in MPZ in the index patient. MPZ sequencing in parents revealed a similar heterozygous variant in MPZ in the patient’s father only.

Conclusions: We presented a novel MPZ variant causing autosomal dominant CMT2I. The pathogenicity of this mutation is supported by its consistency with the clinical phenotype, segregation with disease in the patient’s family, and the male-to-male transmission. In addition, in silico analysis of the variant using SIFT and Polyphen algorithms identify the variant as deleterious and probably damaging respectively.

Disclosure: Dr. Kushlaf has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, PTC therapeutics, Genzyme, and Strongbridge Biopharma.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise